Replies to post #79172 on DNAprint Genomics (DNAG)

[frogdreaming]

I have misconstrued nothing. You are making up connections out of thin air.

The risk of these reactions is estimated to be about 1 to 6 per 10,000 new users of the drug in countries with mainly white populations. However, the risk is estimated to be about 10 times higher in some Asian countries.

The risk is that in people of Asian ancestry up to 60 users in 10,000 are at risk of adverse reactions. The cause of that reaction is a genetic variation that can be tested for using a specific test. DNAG does not make that test.

All DNAG can do is provide a very crude measure of Asian Ancestry. Believe it or not, MOST people with Asian Ancestry are already aware of it. If they wish to take Carbamazine those with such ancestry will need to take a specific genetic test they will not need DNAG.

This constant and unrelenting attempt to twist unrelated events into some semblance of hype is an obvious and seemingly desperate attempt to bend investors perceptions. Why do you suppose it continues in light of the current status quo?